Aclaris Therapeutics News

Analysts Offer Insights on Healthcare Companies: Connect Biopharma Holdings (CNTB), Aethlon Medical (AEMD) and Aclaris Therapeutics (ACRS)

TipRanksMar 4 19:31

Aclaris Therapeutics: Cautious Hold Rating Amid Financial Stability and Pipeline Potential

TipRanksMar 4 19:30

Aclaris Therapeutics: Hold Rating Amidst Strategic Review and Clinical Setbacks

TipRanksMar 1 14:08

HW Wainwright Cuts Aclaris to Neutral, Cites Underwhelming Study Data

Seeking AlphaJan 23 06:55

Aclaris Therapeutics Analyst Ratings

BenzingaJan 22 20:13

Aclaris Therapeutics (ACRS) Was Downgraded to a Hold Rating at BTIG

TipRanksJan 16 18:25

Analysts Offer Insights on Healthcare Companies: Xeris Pharmaceuticals (XERS), Aclaris Therapeutics (ACRS) and Quanterix (QTRX)

TipRanksJan 15 13:20

Aclaris Therapeutics Analyst Ratings

BenzingaJan 11 21:10

Aclaris Downgraded at Jefferies Despite Mid-stage Win for Eczema Therapy

Seeking AlphaJan 11 04:09

Analysts Offer Insights on Healthcare Companies: GoodRx Holdings (GDRX), Aclaris Therapeutics (ACRS) and Ocular Therapeutix (OCUL)

TipRanksJan 2 20:02

Aclaris Therapeutics Analyst Ratings

BenzingaDec 29, 2023 22:24

Buy Rating Justified by Aclaris Therapeutics' Strategic Focus and Robust Financial Management

TipRanksDec 29, 2023 21:45

Stifel Nicolaus Keeps Their Hold Rating on Aclaris Therapeutics (ACRS)

TipRanksDec 21, 2023 10:05

Stifel Maintains Hold on Aclaris Therapeutics, Lowers Price Target to $1

BenzingaDec 18, 2023 22:22

Aclaris Therapeutics Analyst Ratings

BenzingaDec 18, 2023 22:21

HC Wainwright & Co. Maintains Buy on Aclaris Therapeutics, Lowers Price Target to $9

BenzingaNov 14, 2023 22:32

Aclaris Therapeutics Analyst Ratings

BenzingaNov 14, 2023 22:30

Hold Rating on Aclaris Therapeutics: Unfavorable ATI-450 Trial Results and Uncertainty on Upcoming ATI-1777 Trial

TipRanksNov 14, 2023 17:16

Analysts Offer Insights on Healthcare Companies: Acumen Pharmaceuticals (ABOS), Aclaris Therapeutics (ACRS) and CryoPort (CYRX)

TipRanksNov 14, 2023 08:40

Evercore ISI Cuts Aclaris Therapeutics' Price Target to $3 From $22, Keeps Outperform Rating

MT NewswiresNov 14, 2023 04:00